S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:ITRM

Iterum Therapeutics (ITRM) Stock Price, News & Analysis

$1.54
-0.05 (-3.14%)
(As of 03/28/2024 ET)
Today's Range
$1.49
$1.67
50-Day Range
$1.24
$1.99
52-Week Range
$0.62
$2.50
Volume
225,397 shs
Average Volume
613,186 shs
Market Capitalization
$20.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Iterum Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
289.6% Upside
$6.00 Price Target
Short Interest
Bearish
9.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.15mentions of Iterum Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.04) to ($3.05) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.36 out of 5 stars

Medical Sector

772nd out of 938 stocks

Biotechnology Industry

25th out of 38 stocks

ITRM stock logo

About Iterum Therapeutics Stock (NASDAQ:ITRM)

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

ITRM Stock Price History

ITRM Stock News Headlines

Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Iterum Therapeutics (ITRM) Set to Announce Earnings on Thursday
Iterum Therapeutics Provides Business Update
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Iterum Therapeutics PLC (ITRM)
Q3 2023 Iterum Therapeutics PLC Earnings Call
Iterum Therapeutics GAAP EPS of -$0.30
Recap: Iterum Therapeutics Q3 Earnings
See More Headlines
Receive ITRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
3/28/2024
Next Earnings (Confirmed)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ITRM
Fax
N/A
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+292.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-44,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.29 per share

Miscellaneous

Free Float
12,710,000
Market Cap
$20.56 million
Optionable
Not Optionable
Beta
2.35
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Corey N. Fishman (Age 59)
    President, CEO & Director
    Comp: $1.37M
  • Ms. Judith M. Matthews (Age 54)
    Chief Financial Officer
    Comp: $778.82k
  • Dr. Michael W. Dunne M.D. (Age 64)
    Strategic Advisor & Director
    Comp: $168.15k
  • Dr. Sailaja Puttagunta M.D. (Age 55)
    Chief Medical Officer
    Comp: $755.89k
  • Mr. Tom Loughman Ph.D.
    Senior Vice President of Technical Operations
  • Ms. Louise Barrett
    Senior Vice President of Legal Affairs & Secretary
  • Dr. Steven I. Aronin M.D.
    Senior VP & Head of Clinical Development

ITRM Stock Analysis - Frequently Asked Questions

Should I buy or sell Iterum Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Iterum Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ITRM shares.
View ITRM analyst ratings
or view top-rated stocks.

What is Iterum Therapeutics' stock price target for 2024?

1 brokers have issued 1 year price targets for Iterum Therapeutics' shares. Their ITRM share price targets range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 289.6% from the stock's current price.
View analysts price targets for ITRM
or view top-rated stocks among Wall Street analysts.

How have ITRM shares performed in 2024?

Iterum Therapeutics' stock was trading at $1.97 at the beginning of the year. Since then, ITRM stock has decreased by 21.8% and is now trading at $1.54.
View the best growth stocks for 2024 here
.

Are investors shorting Iterum Therapeutics?

Iterum Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 1,210,000 shares, an increase of 24.1% from the February 29th total of 975,300 shares. Based on an average daily trading volume, of 589,100 shares, the short-interest ratio is currently 2.1 days. Currently, 9.3% of the company's shares are short sold.
View Iterum Therapeutics' Short Interest
.

When is Iterum Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our ITRM earnings forecast
.

How were Iterum Therapeutics' earnings last quarter?

Iterum Therapeutics plc (NASDAQ:ITRM) announced its quarterly earnings data on Friday, November, 12th. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.80 by $1.50. During the same quarter last year, the firm posted ($5.10) EPS.

When did Iterum Therapeutics' stock split?

Iterum Therapeutics shares reverse split before market open on Thursday, August 18th 2022. The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Iterum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iterum Therapeutics investors own include Aeglea BioTherapeutics (AGLE), Viking Therapeutics (VKTX), Acasti Pharma (ACST), Axsome Therapeutics (AXSM), Innovate Biopharmaceuticals (INNT), OPKO Health (OPK), VYNE Therapeutics (VYNE), Fulcrum Therapeutics (FULC), Ocugen (OCGN).

When did Iterum Therapeutics IPO?

Iterum Therapeutics (ITRM) raised $80 million in an IPO on Friday, May 25th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

How do I buy shares of Iterum Therapeutics?

Shares of ITRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ITRM) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners